)

Amphastar Pharmaceuticals (AMPH) investor relations material
Amphastar Pharmaceuticals Wells Fargo 20th Annual Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Company Overview, Strategy, and Business Model
Vertically integrated operations span R&D, manufacturing, and distribution, with 1,500 employees and over a decade as a public entity.
Dual growth strategies include organic pipeline expansion and inorganic growth via strategic acquisitions.
Focus on expanding proprietary pipeline to 50% and biosimilars to 35% by 2026, with ongoing business development.
Emphasis on quality, efficiency, and technology has led to rising net income margins and strong revenue growth from 2018 to 2024.
Revenue reached $732 million in 2024, with adjusted net income margin at 27.4%.
Pipeline Evolution, R&D, and Regulatory Updates
Substantial R&D investment of $351 million over five years supports a diverse and scalable product portfolio.
Six generic pipeline candidates in advanced stages, with several FDA approvals expected between late 2025 and 2026.
In-licensed three new peptide assets targeting oncology and ophthalmology, expanding into high-growth markets.
Iron sucrose launched with capacity constraints limiting market share to 25%, but competitive generic therapy status provides six-month exclusivity.
Teriparatide ANDA on track for Q4 GDUFA date, with AMP007 and other ANDA/BLA filings anticipated through 2026.
Key Products and Commercial Performance
BAQSIMI® acquisition expands the diabetes portfolio and international presence to 26 countries, with projected peak sales of $250–$275 million.
Baqsimi transitioned to full control, achieving double-digit script growth and high single-digit unit growth guidance for the year.
Primatene MISTⓇ, the only FDA-approved OTC asthma inhaler, surpassed $100 million in sales in 2024 and is forecasted for continued growth.
Primatene Mist posted 10% year-over-year growth, supported by DTC and physician sampling, with durability expected despite upcoming patent expiry.
Existing products provide a strong revenue base, with new launches supporting diversification.
Next Amphastar Pharmaceuticals earnings date

Next Amphastar Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage